Abstract
Malignant meningiomas are rare neoplasms of the central nervous system that occur de novo or rarely as a result of transformation. They have a higher rate of recurrence and metastasis accompanied by a significantly shorter survivorship compared with benign variants. Meningioma cancer stem cells (CSCs) have been previously shown to be associated with resistance and aggressiveness. However, the role they play in meningioma progression is still being investigated.
We report a 29-year-old man who underwent a resection of a grade I meningioma in 2011. The patient had multiple local recurrences of the tumor that showed an aggressive change in behavior and transformation to grade III meningioma, and developed extracranial metastasis to the cervical spine. He underwent multiple operations and received radiotherapy. Analysis of the tissues indicated the presence of CSC markers before metastasis, and showed increased expressions of associated markers in the metastasized tissue. In addition, similar to the patient's profile, the pharmacological testing of a primary cell line retrieved from the metastasized tissues showed a high level of drug tolerance and a diminished ability to initiate apoptosis.
Malignant progression of grade I meningioma can occur, and its eventuality may be anticipated by detecting CSCs. We performed a comprehensive literature review of relevant cases and discussed the clinical, diagnostic, and management characteristics of the reported cases.
•Malignant meningiomas, as de novo or transformed from a benign variant, is a rare occurrence.•A case of a grade I convexity meningioma in a 29-year-old man that transformed and metastasized to the spine is reported.•In situ immunofluorescence analysis of tissues detected CSCs before and after metastasis.•Live cells retrieved from the metastasized tissues retained CSCs markers, were drug resistant and diminished apoptosis.•Diagnostic detection of CSCs may prove valuable in predicting recurrence or malignant transformation of grade I meningiomas.